ASTRAZENECA PHARMA share price has zoomed 7% and is presently trading at Rs 7,933.6.
Meanwhile, the BSE HEALTHCARE index is at 43,674.5 (up 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are Natco Pharma (up 2.7%) and MAX HEALTHCARE INSTITUTE (up 1.5%).
Jubilant Pharmova (down 2.7%) and ALEMBIC PHARMA (down 1.8%) are among the top losers today.
Over the last one year, ASTRAZENECA PHARMA has moved up from Rs 4,532.7 to Rs 7,933.6, registering a gain of Rs 3,401.0 (up 75.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,428.9 to 43,674.5, registering a gain of 53.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 149.1%), SUVEN PHARMACEUTICALS (up 106.3%) and Glenmark Pharma (up 99.9%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,927.3 (up 0.3%).
The top gainers among the BSE Sensex today are ITC (up 1.7%) and Kotak Bank (up 1.2%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 25,082.7 (up 0.3%). ITC and Kotak Bank are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,512.1 to 81,927.3, registering a gain of 16,415.2 points (up 25.1%).
ASTRAZENECA PHARMA net profit fell 121.9% YoY to Rs -118 million for the quarter ended June 2024, compared to a profit of Rs 539 million a year ago. Net sales rose 31.2% to Rs 3,875 million during the period as against Rs 2,955 million in April-June 2023.
For the year ended March 2024, ASTRAZENECA PHARMA reported 62.7% increase in net profit to Rs 1,615 million compared to net profit of Rs 993 million during FY23. Revenue of the company grew 29.2% to Rs 12,955 million during FY24.
The current Price to earnings ratio of ASTRAZENECA PHARMA, based on rolling 12 month earnings, stands at 206.9.
Equitymaster requests your view! Post a comment on "ASTRAZENECA PHARMA Gains 7%; BSE HEALTHCARE Index Up 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!